| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
We demonstrated that severity of hand-foot skin reaction induced by regorafenib was significantly associated with sum of trough concentrations of regorafenib and its active metabolites M2/M-5. Furthermore, the cutoff value to predict the development of this adverse event (grade 2 or higher) appeared to be approximately 5 μg/mL. It was clarified that pharmacokinetically-guided dosing of pazopanib with therapeutic drug monitoring (TDM) significantly prolonged the duration of treatment with reduced toxicity, as compared with the historical control group.
These findings suggest that TDM could be a useful tool to optimize targeted anticancer therapies by avoiding early discontinuation due to intolerable toxicity.
|
